Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Tyrosine Kinase Inhibitor (TKI) Switching Patterns during the First 12 Months in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Stuart Goldberg, MD, Mauricette Michallet, MD PhD, Rudiger Hehlmann, MD, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Aimee Foreman, Brian Calimlim, Ron Paquette, MD, Bengt Simonsson, MD, Carlo Gambacorti, MD PhD, Jorge E. Cortes, MD, Aleksandra Zagorska, Yuanxin Rong, Michael J. Mauro, MD

Blood (2016) 128 (22): 937.

https://doi.org/10.1182/blood.V128.22.937.937

Published: 2016

Journal Articles

Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis

John O Mascarenhas, MD MS, Moshe Talpaz, Vikas Gupta, MD FRCP, FRCPath, Lynda M Foltz, MD FRCP, Michael R Savona, MD, Ron Paquette, MD, Robert Turner, MD, Paul Coughlin, PhD MBBS, Elliott Winton, MD, Deborah Hunter, PhD, Albert Assad, MD, Jason Clark, PhD, Peter O'Neill, MBA, CCRP, Ronald Hoffman, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 714.

https://doi.org/10.1182/blood.V124.21.714.714

Published: 2014

Journal Articles

Baseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY)

Jorge E. Cortes, MD, Rüdiger Hehlmann, MD, Carlo Gambacorti-Passerini, MD, Stuart Goldberg, MD, H. Jean Khoury, MD, Michael Mauro, MD, Mauricette Michallet, MD, PhD, Ron Paquette, MD, PhD, Bengt Simonsson, MD, PhD, Aimee Foreman, PhD, Hesham Mohamed, MD, Teresa Zyczynski, Pharm.D., MPH, Ishan Hirji, MPH, Catherine Davis, Pharm.D.

Blood (2013) 122 (21): 4026.

https://doi.org/10.1182/blood.V122.21.4026.4026

Published: 2013

Journal Articles

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Blood (2012) 120 (21): 163.

https://doi.org/10.1182/blood.V120.21.163.163

Published: 2012

Journal Articles

Increased Group B Killer Cell Immunoglobulin-Like Receptor (KIR) Haplotypes with Mismatched MHC Class I and Altered NK Repertoire Distribution in Bone Marrow Failure Syndromes

Jeffrey S Painter, BS, Jong Park, PhD, Michael J Clemente, Christine L. O'Keefe, PhD, Sheng Wei, MD, Jaroslaw P. Maciejewski, MD, PhD, Ron Paquette, MD, PhD, Thomas P. Loughran, Jr., M.D., Alan F. List, MD, Pearlie K Epling-Burnette, PhD

Blood (2011) 118 (21): 2412.

https://doi.org/10.1182/blood.V118.21.2412.2412

Published: 2011

Journal Articles

Quality of Life During Early Tyrosine Kinase Inhibitor Treatment As Self-Reported by Chronic Myeloid Leukemia Patients Participating in a Prospective Observational Study (SIMPLICITY)

Jorge E. Cortes, Michael J. Mauro, MD, Stuart L. Goldberg, MD, Ron Paquette, MD, PhD, H. Jean Khoury, MD, FACP, Ishan Hirji, MPH, Samuel Wagner, PhD, RPh, Sam Joo, PhD, Catherine Davis, PharmD

Blood (2011) 118 (21): 4435.

https://doi.org/10.1182/blood.V118.21.4435.4435

Published: 2011

Journal Articles

Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation

Blood (2011) 118 (21): 109.

https://doi.org/10.1182/blood.V118.21.109.109

Published: 2011

Journal Articles

GWAS Indicates the Presence of Rare Immunogenetic Polymorphisms as Possible Predisposition Factors in Aplastic Anemia.

Bartlomiej P Przychodzen, Monika Jasek, PhD, Sandra P Smieszek, Ron Paquette, MD, Rainer Richter, Manuel Afable, R.N., Jaroslaw P. Maciejewski, MD, PhD

Blood (2009) 114 (22): 1093.

https://doi.org/10.1182/blood.V114.22.1093.1093

Published: 2009

Journal Articles

Identification of Genetic Polymorphisms Contributing to Risk in MDS Using Innovative GWAS Approaches.

Sandra P Smieszek, Bartlomiej P Przychodzen, Ron Paquette, MD, Rainer Richter, Manuel Afable, R.N., Jaroslaw P. Maciejewski, MD, PhD

Blood (2009) 114 (22): 734.

https://doi.org/10.1182/blood.V114.22.734.734

Published: 2009

Journal Articles

Clonal Hematopoiesis in Philadelphia Chromosome-Negative Bone Marrow Cells of Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors

Ron Paquette, MD, John Nicoll, Meenal Chalukya, Lukasz P Gondek, MD, PhD, Monika Jasek, Charles Sawyers, MD, Neil Shah, MD, PhD, Jaroslaw Maciejewski

Blood (2008) 112 (11): 575.

https://doi.org/10.1182/blood.V112.11.575.575

Published: 2008

Journal Articles

Dysregulated Distribution of Naïve and Memory FoxP3 Positive Regulatory T-Cells Associated with Anemia in Myelodysplastic Syndrome (MDS)

Chiharu Sugimori, MD, JianXiang Zou, MD, Christine O’Keefe, PhD, Michael Clemente, MS, Tie-Ying Wei, BS, Jaroslaw Maciejewski, Thomas P. Loughran, Jr., MD, Ron Paquette, MD, Alan F. List, MD, P.K. Epling-Burnette, PhD

Blood (2008) 112 (11): 3654.

https://doi.org/10.1182/blood.V112.11.3654.3654

Published: 2008

Journal Articles

Genetic Disparities in Killer Cell Immunoglobulin-Like Receptors (KIR) and MHC Class I in Bone Marrow Failure Syndromes

P.K. Epling-Burnette, PhD, Jeffrey S. Painter, BS, H.-S. Lee, PhD, Jong Park, Michael Clemente, MS, Christine O’Keefe, MD, Tie-Ying Wei, BS, Sheng Wei, MD, Jaroslaw Maciejewski, Thomas P. Loughran, Jr., MD, Ron Paquette, MD, Alan F. List, MD, Julie Y Djeu, PhD

Blood (2008) 112 (11): 4121.

https://doi.org/10.1182/blood.V112.11.4121.4121

Published: 2008

NARROW

Tyrosine Kinase Inhibitor (TKI) Switching Patterns during the First 12 Months in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients (Pts) in Routine Clinical Practice

Primary Analysis Results from an Open-Label Phase II Study of INCB039110, a Selective JAK1 Inhibitor, in Patients with Myelofibrosis

Baseline Characteristics Of Patients With Chronic Myeloid Leukemia In a Prospective Observational Study (SIMPLICITY)

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Increased Group B Killer Cell Immunoglobulin-Like Receptor (KIR) Haplotypes with Mismatched MHC Class I and Altered NK Repertoire Distribution in Bone Marrow Failure Syndromes

Quality of Life During Early Tyrosine Kinase Inhibitor Treatment As Self-Reported by Chronic Myeloid Leukemia Patients Participating in a Prospective Observational Study (SIMPLICITY)

Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation

GWAS Indicates the Presence of Rare Immunogenetic Polymorphisms as Possible Predisposition Factors in Aplastic Anemia.

Identification of Genetic Polymorphisms Contributing to Risk in MDS Using Innovative GWAS Approaches.

Clonal Hematopoiesis in Philadelphia Chromosome-Negative Bone Marrow Cells of Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitors

Dysregulated Distribution of Naïve and Memory FoxP3 Positive Regulatory T-Cells Associated with Anemia in Myelodysplastic Syndrome (MDS)

Genetic Disparities in Killer Cell Immunoglobulin-Like Receptors (KIR) and MHC Class I in Bone Marrow Failure Syndromes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only